ATP-binding cassette sub-family B member 1 (ABCB1) Genotyping
The ABCB1 gene encodes a membrane-associated transporter of the ATP-binding cassette family (also known as P-gp), an ATP-dependent efflux pump with broad substrate specificity. The protein is highly expressed in the intestine and kidney, where it impacts the absorption and excretion of many drugs. Some cancer cells also express large amounts of P-gp, which renders these cancers multi-drug resistant. P-gp is also a significant component of the blood–brain barrier and numerous studies have evaluated genetic variation in the ABCB1 gene as a possible pharmacogenetic marker for antipsychotics.
The three most common SNPs in the protein coding region are rs1128503 (1236T>C, Gly412Gly), rs2032582 (2677T>G/A, Ser893Ala/Thr), and rs1045642 (3435T>C, Ile1145Ile). These three SNPs are in high linkage disequilibrium (tend to be inherited together) and have been the focus of many pharmacokinetic and disease association studies.
Drug resistance accounts for more than 90% of treatment failures in metastatic cancer. Multi-drug resistance from intrinsic (drug-naive) and acquired (drug-induced) over-expression of P-gp is a notable impediment to brain-targeted therapies (e.g. antiepileptics, neuro-antiretrovirals) and chemotherapies. P-gp expression predicts between 30 to 40% of treatment failure in epilepsy and is correlated with drug non-response in acute myeloid leukemia, childhood neuroblastoma and sarcoma, and other cancers.
Most of the second generation antipsychotic drugs are substrates for P-gp. Caucasian individuals homozygous for the rs1045642 (3435T>C, Ile1145Ile) allele have significantly reduced activity for the transporter, likely as a result of the strong linkage disequilibrium with the functional rs2032582 (2677T>G/A, Ser893Ala/Thr) missense variant. Thus, the 3435T>C (and 2677T>G/A) variants are expected to correlate with higher serum levels of the drugs due to decreased export function in the intestine and kidney.
- Prediction and risk assessment for multi-drug resistance in multiple cancers
- Prediction and risk assessment for multi-drug resistance in epilepsy
- Risk assessment and dosage guidance for second generation antipsychotic drugs
- Presence of the 2 and 13 alleles is indicative of reduced transporter function.
- Multi-drug resistance is most frequently observed in wild-type individuals (1/1).
- Lower doses of anti-psychotic drugs should be considered for patients with the 2 and/or 13 alleles. *ABCB11 contains 1236C, 2677G (893Ala), 3435C* ABCB12 contains 1236T, 2677T (893Ser), 3435T* ABCB113 contains 1236T, 2677T (893Ser), 3435T, and three intronic SNPs**
Wild-type: 3435C>T T/T (*1/*1)
Buccal swabs or Whole blood (ACD yellow top tube is preferred, EDTA lavender top tube also accepted)
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Pharmacogenet Genomics. 2011; 21(3):152-61. [PMID: 20216335]
- Rev Invest Clin. 2013 Sep-Oct;65(5):445-54. [PMID: 24687344]
- J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):68-77. [PMID: 24285312]
- J Int Med Res. 2012;40(2):426-35. [PMID: 22613403]
- Arch Pharm Res. 2011 Nov;34(11):1817-28. [PMID: 22139683]
- Curr Pharm Des. 2011;17(26):2843-51. [PMID: 21827404]
- Pharmacogenomics. 2011 May;12(5):713-25. [PMID: 21391884]